Pacira BioSciences (FRA:82P) EPS (Basic): €0.10 (TTM As of Mar. 2026)


FRA:82P Pacira BioSciences Inc FRA:82P
74 GF Score
Price €20.60
GF Value €24.22
! 6 Warning Signs
View Full Analysis

What is Pacira BioSciences EPS (Basic)?

Pacira BioSciences FRA:82P +6.74% 74 EPS (Basic) is €0.10 as of Mar. 2026. GuruFocus rates FRA:82P with a GF Score™ of 74/100 and a GF Value™ of €24.22. The stock has 6 warning signs investors should review.

Pacira BioSciences's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €0.06. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.10.

Pacira BioSciences's EPS (Diluted) for the three months ended in Mar. 2026 was €0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.10.

Pacira BioSciences's EPS without NRI for the three months ended in Mar. 2026 was €0.52. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 1.87.

During the past 12 months, Pacira BioSciences's average EPS without NRIGrowth Rate was 99.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 0.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was 19.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Pacira BioSciences's highest 3-Year average EPS without NRI Growth Rate was 119.10% per year. The lowest was -20.50% per year. And the median was 9.45% per year.

Pacira BioSciences  (FRA:82P) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Pacira BioSciences EPS (Basic) Related Terms

Pacira BioSciences EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences EPS (Basic) Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.84 0.33 0.83 -2.05 0.14

Pacira BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 -0.10 0.10 0.03 0.06
FRA:82P
74GF Score
Pacira BioSciences Inc FRA:82P
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Pacira BioSciences's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(6.007-0)/44.566
=0.13

Pacira BioSciences's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(2.522-0)/40.461
=0.06

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €0.10 mean?
Pacira BioSciences (FRA:82P) has a EPS (Basic) of €0.10 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' EPS (Basic) too high?
Pacira BioSciences' current EPS (Basic) is €0.10. Overall, Pacira BioSciences has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' EPS (Basic) compare to ETON and AMPH?
Pacira BioSciences' EPS (Basic) of €0.10 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current EPS (Basic) is €0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current EPS (Basic) of €0.10. The stock's GF Value™ is €24.22, compared to a current price of €20.60 — trading 14.9% below its estimated fair value. The current EPS (Basic) is €0.10. Pacira BioSciences' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current EPS (Basic) is €0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €20.60 is trading 14.9% below its estimated GF Value™ of €24.22.

Key valuation signals for FRA:82P:

  • EPS (Basic): €0.10
  • GF Value™: €24.22 vs. price of €20.60 (14.9% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
74GF Score

Get the complete analysis for FRA:82P

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.60
Price
€24.22
GF Value